Theravance Bio Ord (TBPH) Stock Price, Quote & News

Company Profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a str...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 808 6000

Website: www.theravance.com

Address:

901 Gateway Boulevard, South San Francisco, United States

JarvisFlow Dec. 3 at 4:31 PM

Oppenheimer updates rating for Theravance Biopharma ( $TBPH ) to Outperform, target set at 27.

0 · Reply

SuperGreenToday Dec. 3 at 3:16 PM

$TBPH Share Price: $18.80 Contract Selected: Jun 18, 2026 $20 Calls Buy Zone: $1.57 – $1.94 Target Zone: $2.97 – $3.63 Potential Upside: 78% ROI Time to Expiration: 196 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Quantumup Dec. 3 at 11:34 AM

Oppenheimer🏁 $TBPH Outperform/$27 $VTRS $HLUBF $HLBBF TAK $GSK AZN Oppenheimer said, We are launching on Theravance Biopharma at Outperform with a $27 PT. We see potential for the company's 1Q26 Phase 3 ampreloxetine readout to be transformative with a positive risk/reward into topline data. Our 50% PoS supports ~50% upside potential, and approval would likely support a roughly doubling of our valuation expectations. Downside risk is offset with Yupelri supporting the company at near cash flow breakeven, along with an anticipated pro forma cash balance after royalty milestones of ~$500M. Theravance shares have bid up over the past month (+26% vs. XBI's +5%) into Phase 3 data as we believe investors are taking notice of the transformative potential and mechanistic rationale, along with the downside protection. Positive Phase 3 data would likely support positive re-rating with $1B+ sales potential.

0 · Reply

Drashkawisha Dec. 3 at 9:23 AM

$TBPH Eran Broshy, a 10% owner and director of Theravance Biopharma, sold a total of 29,501 ordinary shares on November 26, 2025, at a price of $20.0 per share, resulting in a total sale amount of $590,020. Following these transactions, Broshy directly owns 44,703 ordinary shares of the company.

0 · Reply

Estimize Dec. 2 at 9:00 PM

Wall St is expecting 1.00 EPS for $TBPH Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/tbph?chart=historical&metric_name=eps&utm_co

0 · Reply

anachartanalyst Nov. 26 at 1:02 PM

$TBPH https://anachart.com/wp-content/uploads/ana_temp/1764162091_soc-img.jpg

0 · Reply

JarvisFlow Nov. 26 at 12:10 PM

BTIG has adjusted their stance on Theravance Biopharma ( $TBPH ), setting the rating to Buy with a target price of 25 → 40.

0 · Reply

InItToWinIt100 Nov. 24 at 4:33 AM

Watchlist for the morning $HLF $FLGT $TBPH $WALD $CTSH

0 · Reply

Drashkawisha Nov. 19 at 2:08 PM

$HRTX Stop looking at the rear-view mirror (revenue miss) and look at the windshield. Here is the alpha nobody is talking about: Insiders are FEASTING: Insider transaction volume is +246%. Management is loading the boat at these levels. Do they like losing money? No. They know what's coming. Deep Value: Trading at ~1.3x Sales. This is priced for bankruptcy, but the 10-Q shows they just turned the corner on cash burn. The risk/reward here is insane. The "TBPH" Setup: Massive operational efficiency + pivot to profitability. This is the exact same setup that sent $TBPH flying. Shorts are playing with fire here. One PR and this explodes. Loading the dip. Long & Strong. 🐂💎

2 · Reply

Drashkawisha Nov. 18 at 4:14 PM

$TBPH need this to go back to 16$ so I can enter.

0 · Reply

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

Nov 19, 2025, 6:00 AM EST - 15 days ago

Theravance Biopharma to Participate in Upcoming Investor Conferences

Nov 11, 2025, 2:14 PM EST - 23 days ago

Here's Why Shares in Theravance Biopharma Exploded Today

Nov 11, 2025, 4:04 AM EST - 24 days ago

Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:05 PM EST - 24 days ago

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 6:00 AM EDT - 5 weeks ago

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

Oct 27, 2025, 6:00 AM EDT - 5 weeks ago

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

Oct 16, 2025, 8:05 AM EDT - 7 weeks ago

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

Oct 14, 2025, 6:00 AM EDT - 7 weeks ago

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

Sep 2, 2025, 6:00 AM EDT - 3 months ago

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 6:00 AM EDT - 3 months ago

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

Aug 12, 2025, 6:52 PM EDT - 4 months ago

Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 28, 2025, 6:00 AM EDT - 4 months ago

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 23, 2025, 6:00 AM EDT - 4 months ago

Theravance Biopharma to Participate in an Upcoming Investor Conference

Jun 26, 2025, 6:00 AM EDT - 5 months ago

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

Jun 2, 2025, 6:00 AM EDT - 6 months ago

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

GSK

May 10, 2025, 4:35 PM EDT - 7 months ago

Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript

May 9, 2025, 12:00 PM EDT - 7 months ago

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

May 8, 2025, 4:05 PM EDT - 7 months ago

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 6:00 AM EDT - 7 months ago

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

Apr 24, 2025, 6:00 AM EDT - 8 months ago

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 7, 2025, 3:55 PM EDT - 8 months ago

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

Mar 27, 2025, 6:00 AM EDT - 9 months ago

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

Feb 26, 2025, 8:58 PM EST - 10 months ago

Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 10 months ago

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 6:00 AM EST - 10 months ago

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Dec 17, 2024, 6:00 AM EST - 1 year ago

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Nov 12, 2024, 10:46 PM EST - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

Oct 24, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

Oct 18, 2024, 9:00 AM EDT - 1 year ago

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease

Aug 5, 2024, 7:37 PM EDT - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:05 PM EDT - 1 year ago

Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024

May 13, 2024, 6:58 PM EDT - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:05 PM EDT - 1 year ago

Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 29, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024

Apr 10, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

Feb 26, 2024, 9:52 PM EST - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:05 PM EST - 1 year ago

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 14, 2024, 6:00 AM EST - 1 year ago

Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Jan 5, 2024, 6:15 AM EST - 2 years ago

Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal

Jan 5, 2024, 6:00 AM EST - 2 years ago

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Dec 21, 2023, 5:00 PM EST - 2 years ago

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

Dec 18, 2023, 6:00 AM EST - 2 years ago

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference

Nov 16, 2023, 6:00 AM EST - 2 years ago

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System

Nov 15, 2023, 6:00 AM EST - 2 years ago

Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 8:00 AM EST - 2 years ago

Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

VTRS

Nov 7, 2023, 11:23 PM EST - 2 years ago

Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript

JarvisFlow Dec. 3 at 4:31 PM

Oppenheimer updates rating for Theravance Biopharma ( $TBPH ) to Outperform, target set at 27.

0 · Reply

SuperGreenToday Dec. 3 at 3:16 PM

0 · Reply

Quantumup Dec. 3 at 11:34 AM

0 · Reply

Drashkawisha Dec. 3 at 9:23 AM

0 · Reply

Estimize Dec. 2 at 9:00 PM

Wall St is expecting 1.00 EPS for $TBPH Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/tbph?chart=historical&metric_name=eps&utm_co

0 · Reply

anachartanalyst Nov. 26 at 1:02 PM

$TBPH https://anachart.com/wp-content/uploads/ana_temp/1764162091_soc-img.jpg

0 · Reply

JarvisFlow Nov. 26 at 12:10 PM

BTIG has adjusted their stance on Theravance Biopharma ( $TBPH ), setting the rating to Buy with a target price of 25 → 40.

0 · Reply

InItToWinIt100 Nov. 24 at 4:33 AM

Watchlist for the morning $HLF $FLGT $TBPH $WALD $CTSH

0 · Reply

Drashkawisha Nov. 19 at 2:08 PM

2 · Reply

Drashkawisha Nov. 18 at 4:14 PM

$TBPH need this to go back to 16$ so I can enter.

0 · Reply

StockScanners Nov. 15 at 4:36 AM

$TBPH reached 18.20

0 · Reply

Drashkawisha Nov. 13 at 8:24 AM

$TBPH Alright team, need your help breaking this down. I'm seeing a lot of positive noise around the Q3 earnings, the big cash pile ($333M), and the stable YUPELRI revenue. Great. But the real story here is the Ampreloxetine Phase 3 (CYPRESS) data in Q1 2026, right? My question: The previous trial (0170) officially failed. But I see they showed strong data (OR 0.28) in the MSA patient subgroup. Is the current CYPRESS trial just a "clean" repeat on only that group? Is this really considered "de-risked"? And what about the competition? The incumbents (Northera/Midodrine) are carrying a Black Box Warning for supine hypertension. I read $TBPH doesn't have this safety issue. Is that the real clinical differentiation? Bottom line: If the science is strong, there's no dilution risk, and the competition is weak – why is the market sleeping on this? What am I missing? Seriously looking for the Bear Case here. Explain it to me.

0 · Reply

d_risk Nov. 12 at 10:24 PM

$TBPH - Theravance Biopharma Inc. Ordinary Shares - 10Q - Updated Risk Factors TBPH’s updated 10-Q risk factors spotlight higher US co-promotion costs and sales hurdles for YUPELRI, broader clinical trial and regulatory risks, expanded litigation and patent challenges, new FDA transparency threats, and heightened exposure to shifting healthcare laws and pricing pressures, while trimming tax and environmental risks. #Biopharma #PatentLitigation #HealthcarePricing #RegulatoryRisks #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/TBPH/10-Q/2025-11-12

0 · Reply

StockScanners Nov. 12 at 2:36 AM

$TBPH keep watch if this holds above 17.30

0 · Reply

Maximillion26 Nov. 11 at 9:30 PM

$TBPH

1 · Reply

topstockalerts Nov. 11 at 7:32 PM

$TBPH following closely 🚨

0 · Reply

ZacksResearch Nov. 11 at 4:36 PM

$TBPH beats Q3 earnings expectations — but that’s not the whole story. 💥 Revenue climbed 19%, powered by stronger collaboration income from Viatris tied to Yupelri sales — a solid sign of operational traction. Full Q3 breakdown here 👉 https://www.zacks.com/stock/news/2789369/theravances-q3-earnings-surpass-estimates-revenues-match?cid=sm-stocktwits-2-2789369-teaser-20508&ADID=SYND_STOCKTWITS_TWEET_2_2789369_TEASER_20508

0 · Reply

ZacksResearch Nov. 11 at 3:36 PM

$TBPH posts a surprise Q3 profit — what's fueling the rally? 🚀 Theravance Biopharma reported Q3 adjusted earnings of 4 cents per share, smashing the Zacks Consensus Estimate of a loss of 3 cents, driven by 19% growth in collaboration revenues with Viatris. Year to date, shares have surged 60.2% compared to the industry's 2.7% rise. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2789369/theravances-q3-earnings-surpass-estimates-revenues-match?cid=sm-stocktwits-2-2789369-body-20506&ADID=SYND_STOCKTWITS_TWEET_2_2789369_BODY_20506

0 · Reply

JarvisFlow Nov. 11 at 12:27 PM

HC Wainwright & Co. updates rating for Theravance Biopharma ( $TBPH ) to Buy, target set at 15 → 20.

0 · Reply

G101SPM Nov. 5 at 7:20 PM

#SHOWTIME American Autonomic Society Autonomic Nervous System International Symposium (November 6-8) Scheduled to appear: $TBPH

0 · Reply

ZacksResearch Oct. 30 at 7:10 PM

$CRMD vs. $TBPH: Which small-cap biotech is your best bet? 🤔 CorMedix shines with DefenCath driving impressive growth, supported by a robust, diversified growth strategy. Meanwhile, Theravance leans heavily on its Viatris tie-up, with risks tied to a single pipeline drug. See what makes CRMD the more compelling pick 👉 https://www.zacks.com/stock/news/2781911/crmd-vs-tbph-which-small-cap-biotech-stock-is-the-better-buy?cid=sm-stocktwits-2-2781911-body-18706&ADID=SYND_STOCKTWITS_TWEET_2_2781911_BODY_18706

0 · Reply

ZacksResearch Oct. 30 at 6:10 PM

$CRMD vs. $TBPH — two small-cap biotechs, two very different growth stories 💥 CorMedix is leaning on sales traction, while Theravance is banking on its pipeline potential to drive the next leg higher. See which small-cap biotech looks like the better buy 👉 https://www.zacks.com/stock/news/2781911/crmd-vs-tbph-which-small-cap-biotech-stock-is-the-better-buy?cid=sm-stocktwits-2-2781911-teaser-18672&ADID=SYND_STOCKTWITS_TWEET_2_2781911_TEASER_18672

0 · Reply

Market Cap	933.89M
Revenue (ttm)	64.38M
Net Income (ttm)	-56.42M
EPS (ttm)	N/A
PE Ratio	39.21
Forward PE	N/A
Profit Margin	-87.64%
Debt to Equity Ratio	0.00

Volume	331,200
Avg Vol	434,466
Day's Range	N/A - N/A
Shares Out	50.67M
Stochastic %K	42%
Beta	0.14
Analysts	Strong Sell
Price Target	$24.00